Evaluation of the effect of febuxostat on endothelial dysfunction in hemodialysis
Mona Al-Shahawey Al-Sayed Ghazy;
Abstract
Abstract
Background:
Endothelial dysfunction is an important risk factor for developing cardiovascular diseases in End Stage Renal Disease (ESRD) patients. Febuxostat; being a novel xanthine oxidase inhibitor, is apparently having a beneficial role in improving endothelial dysfunction, however, data among hemodialysis patients is still limited.
Methods:
A prospective, placebo controlled, block randomized double blinded study was carried out to evaluate the effect of oral febuxostat on endothelial dysfunction in hemodialysis patients. Fifty-seven eligible hemodialysis patients were randomly assigned to either drug group (40 mg thrice weekly) or placebo group. Serum Asymmetric dimethylarginine (ADMA), serum uric acid (UA) and serum high sensitivity C-reactive protein (HsCRP) were measured at baseline and at the end of a two months study. Serum Alanine Aminotransferase (ALT), serum Aspartate Aminotransferase (AST) and occurrence of pancytopenia were tested as safety parameters at baseline and at the end of study.
Results:
Serum UA significantly decreased from 7.5 ± 0.8 mg/dL to 5.1 ± 1.2 mg/dL in Febuxostat group while it didn’t change significantly in placebo group. Treatment with Febuxostat resulted in a significant decrease in serum ADMA level from (1.027 ± 0.116 µmol/L to 0.944 ± 0.104 µmol/L) and serum HsCRP level from (12.5 ± 1.65 mg/L to 12.1 ± 1.70 mg/L). Testing of serum ALT, serum AST and pancytopenia revealed no significant difference in both groups.
Background:
Endothelial dysfunction is an important risk factor for developing cardiovascular diseases in End Stage Renal Disease (ESRD) patients. Febuxostat; being a novel xanthine oxidase inhibitor, is apparently having a beneficial role in improving endothelial dysfunction, however, data among hemodialysis patients is still limited.
Methods:
A prospective, placebo controlled, block randomized double blinded study was carried out to evaluate the effect of oral febuxostat on endothelial dysfunction in hemodialysis patients. Fifty-seven eligible hemodialysis patients were randomly assigned to either drug group (40 mg thrice weekly) or placebo group. Serum Asymmetric dimethylarginine (ADMA), serum uric acid (UA) and serum high sensitivity C-reactive protein (HsCRP) were measured at baseline and at the end of a two months study. Serum Alanine Aminotransferase (ALT), serum Aspartate Aminotransferase (AST) and occurrence of pancytopenia were tested as safety parameters at baseline and at the end of study.
Results:
Serum UA significantly decreased from 7.5 ± 0.8 mg/dL to 5.1 ± 1.2 mg/dL in Febuxostat group while it didn’t change significantly in placebo group. Treatment with Febuxostat resulted in a significant decrease in serum ADMA level from (1.027 ± 0.116 µmol/L to 0.944 ± 0.104 µmol/L) and serum HsCRP level from (12.5 ± 1.65 mg/L to 12.1 ± 1.70 mg/L). Testing of serum ALT, serum AST and pancytopenia revealed no significant difference in both groups.
Other data
| Title | Evaluation of the effect of febuxostat on endothelial dysfunction in hemodialysis | Authors | Mona Al-Shahawey Al-Sayed Ghazy | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.